| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Feb, 2026 | Feb, 2026 |
| Sales | 27,340 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -93,740 | -87,010 | -59,940 | 0 | 0 |
| Net Income Growth | -7.73% | -45.16% | unch | unch | unch |
Vectivbio Holding Ag
(VECT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need. VectivBio Holding AG is based in BASEL, Switzerland.
Fiscal Year End Date: 12/31